Autologous
Cell Therapy
Gene Therapy
Logistics

The Thawing Dilemma: Where and How Should We Be Thawing Advanced Therapy Products?

Phacilitate
3 August 2020
SHARE NOW

In this presentation, Joseph examines the requirements for bedside vs. laboratory thawing and their respective advantages and disadvantages.

Advanced Therapies Week

2022, Miami, Florida.
Book Today

A presentation with Joseph Schwartz, MD, MPH, Director, Transfusion Medicine and Cellular Therapy at New York-Presbyterian Hospital and Columbia University

When shipping and administering advanced therapies, cryopreservation is needed in most situations, especially for autologous products.

In this presentation, Joseph examines the requirements for bedside vs. laboratory thawing and their respective advantages and disadvantages. A balance is required between the speed of getting the therapies to patients and the viability of the cells to be administered, with the goal being to avoid osmotic stress and cell lysis. Post-thaw removal procedures are critical to preventing cell losses.

Joseph goes on to discuss the use of DMSO; a double-edged sword when it comes to cryopreserving products and successful thawing. There is also a new industry benchmark that you don’t exceed 1cc DMSO per kg patient per day.

There are two options to reduce potential damages:
Reduce the time that cells are exposed to DMSO while thawing
Reduce the DMSO concentration

We end with a review of the thaw request form used by the New York-Presbyterian Hospital.

Advanced Therapies Week

2022, Miami, Florida.
Book Today